Loading stock data…
$7.37+0.20 (+2.79%)
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Grifols, S.A. in the Healthcare sector is trading at $7.37 with a market capitalization of $5.3B. Wall Street consensus targets $10.87 (2 analysts), implying a +47.4% move over the next 12 months. The stock is currently near its 52-week low of $6.96, remaining 8.1% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.87B↑ | $1.70B↓ | $1.98B↑ | $1.89B↑ | $1.79B |
| Gross Profit | $705.00M↑ | $620.00M↓ | $686.84M↓ | $744.00M↑ | $695.00M |
| Operating Income | $329.00M↑ | $249.00M↓ | $275.38M↓ | $350.00M↑ | $274.00M |
| Net Income | $155.00M↑ | $73.00M↓ | $98.25M↓ | $117.00M↑ | $60.00M |
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,...